ABCLAbCellera Biologics Inc.

Nasdaq abcellera.com


$ 4.50 $ 0.20 (4.66 %)    

Wednesday, 27-Mar-2024 15:59:52 EDT
QQQ $ 444.97 $ 1.51 (0.34 %)
DIA $ 397.57 $ 4.71 (1.2 %)
SPY $ 523.27 $ 4.36 (0.84 %)
TLT $ 94.66 $ 0.93 (0.99 %)
GLD $ 203.04 $ 1.46 (0.72 %)
$ 4.49
$ 4.28
$ 0.00 x 0
$ 0.00 x 0
$ 4.28 - $ 4.50
$ 3.87 - $ 8.05
1,337,798
na
1.3B
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-20-2024 12-31-2023 10-K
2 11-02-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-21-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a ...

 benchmark-upgrades-abcellera-biologics-to-buy

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy.

 abcellera-biologics-q4-2023-gaap-eps-017-misses-013-estimate-sales-918m-beat-888m-estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of...

 earnings-scheduled-for-february-20-2024

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue...

 keybanc-initiates-coverage-on-abcellera-biologics-with-overweight-rating-announces-price-target-of-6

Keybanc analyst Scott Schoenhaus initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announ...

 abcellera-presents-new-data-on-two-t-cell-engager-programs-at-sitc-2023

New data from AbCellera's T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T...

 abcellera-biologics-q3-eps-010-beats-013-estimate-sales-660m-miss-1190m-estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-november-2-2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

Core News & Articles

Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) today announced a multi-year, m...

 piper-sandler-assumes-abcellera-biologics-at-overweight-announces-price-target-of-20

Piper Sandler analyst Allison Bratzel assumes AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-monday

  On Monday, 369 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  During Thursday's session, 406 companies made new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 386 stocks made new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION